Figure 4 Contribution of both peripheral- and spinal-located Cav3.2 channels in inflammatory pain
The effect of a systemic administration of ABT-639 (10, 30 or 100 mg/kg, i.p., C, D ) or intraplantar injection of ABT-639 (2.5 µl in 20 µl, E ) or an intrathecal injection of ABT-639 (10 µg in 5 µl,F ) or their respective vehicles (VEH) were evaluated in the carrageenan (A , C ) and CFA (D-F ) models. In all conditions, mice were submitted to the von Frey test to assess mechanical allodynia (left ) and hyperalgesia (right ). Statistical differences were assessed by two-way ANOVA (Time, Genotype or Treatments) followed by Bonferroni post-hoc test [significant differences between VEH and ABT-639 group are indicated by asterisks (*p < 0.05; **p < 0.01; ***p< 0.001)]. Data represent mean ± SEM.